A Study of MVA85A in Healthy Infants

Clinical Trial ID NCT00953927

PubWeight™ 23.23^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00953927

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.	Lancet	2013	8.18
2	Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing.	Clin Vaccine Immunol	2010	1.64
3	Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.	Tuberculosis (Edinb)	2013	1.34
4	Tuberculosis vaccines: beyond bacille Calmette-Guerin.	Philos Trans R Soc Lond B Biol Sci	2011	1.29
5	Tuberculosis vaccines in clinical trials.	Expert Rev Vaccines	2011	1.26
6	Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.	Expert Rev Vaccines	2011	0.98
7	Prime-boost approaches to tuberculosis vaccine development.	Expert Rev Vaccines	2012	0.91
8	T-cell activation is an immune correlate of risk in BCG vaccinated infants.	Nat Commun	2016	0.89
9	Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.	PLoS One	2012	0.87
10	Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.	BMC Infect Dis	2014	0.81
11	Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.	Clin Vaccine Immunol	2014	0.79
12	Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children.	Pediatr Infect Dis J	2015	0.78
13	Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial.	PLoS One	2015	0.77
14	Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations.	Vaccines (Basel)	2014	0.76
15	The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children.	Pediatr Infect Dis J	2015	0.75
16	B Cells and Programmed Death-Ligand 2 Signaling Are Required for Maximal Interferon-γ Recall Response by Splenic CD4⁺ Memory T Cells of Mice Vaccinated with Mycobacterium tuberculosis Ag85B.	PLoS One	2015	0.75
17	Current status of new tuberculosis vaccine in children.	Hum Vaccin Immunother	2016	0.75